Compounds > 2'-o-methylcytidine
Page last updated: 2024-12-08

2'-o-methylcytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID150971
CHEMBL ID176605
CHEBI ID19228
SCHEMBL ID64632
MeSH IDM0148260

Synonyms (32)

Synonym
2'-o-methyl cytidine
4-amino-1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxy-tetrahydrofuran-2-yl]pyrimidin-2-one
4-amino-1-((2r,3r,4s,5r)-4-hydroxy-5-hydroxymethyl-3-methoxy-tetrahydro-furan-2-yl)-1h-pyrimidin-2-one
2'-o-methyl-cytidine
2'-o-methylcytidine ,
o(2')-methylcytidine
2140-72-9
CHEBI:19228 ,
4-amino-1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]pyrimidin-2-one
CHEMBL176605
unii-5xd9ih2g27
5xd9ih2g27 ,
cytidine, 2'-o-methyl-
4-amino-1-((2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)pyrimidin-2(1h)-one
AKOS015896935
AKOS015850975
BRD-K23276845-001-01-1
HG1325
SCHEMBL64632
o-2-methylcytidine
mfcd11519076
DS-14587
4-imino-1-(2-o-methylpentofuranosyl)-1,4-dihydropyrimidin-2-ol
DTXSID50943958
Q15632793
ZB1481
CS-W012550
HY-W011834
PD143476
BP-58836
o2'-methylycytidine
4-azanyl-1-[(2r,3r,4r,5r)-5-(hydroxymethyl)-3-methoxy-4-oxidanyl-oxolan-2-yl]pyrimidin-2-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylcytidineAny member of the class of cytidines that is cytidine substituted by at least one methyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID246380Effective concentration against hepatitis C virus RNA replication in a subgenomic bicistronic replicon in HBI10A cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID658631Inhibition of Hepatitis C virus NS5B RNA-dependent RNA polymerase2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID250331Average intracellular Metabolism was measured in human Huh-7 cells after 23 hr of incubation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID250347Average intracellular Metabolism was measured in human HBI10A cells after 23 hr of incubation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID326208Antiviral activity against Hepatitis C virus infected in human Huh7 AVA5 cells by replicon assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine.
AID245967Cytotoxic concentration of compound in human HBI10A cells infected with hepatitis C virus in MTS assay2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID250318Average intracellular Metabolism was measured in human Huh-7 cells after 3 h of incubation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID326209Cytotoxicity against human Huh7 AVA5 cells2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine.
AID250330Average intracellular Metabolism was measured in human HBI10A cells after 3 h of incubation2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID248115Inhibitory concentration against hepatitis C virus NS5B-mediated RNA synthesis in HBI10A cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.67)18.7374
1990's3 (20.00)18.2507
2000's4 (26.67)29.6817
2010's7 (46.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.78 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		2.110pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		3.1150uridinesdrug metabolite;
fundamental metabolite;
human metabolite
cytidine monophosphate
Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. cytidine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.		2.0210cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
cytidine
[no description available]		3.98130cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytidine triphosphate
Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.0110cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
osmium
Osmium: A very hard, gray, toxic, and nearly infusible metal element, atomic number 76, atomic weight 190.2, symbol Os.		2.1710iron group element atom;
platinum group metal atom
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.0210pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-methyladenosine
[no description available]		210methyladenosinehuman metabolite
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.9640adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
1-methylinosine
1-methylinosine : Inosine carrying a methyl substituent at position 1 on the hypoxanthine ring.		210inosinesmetabolite
5-methylcytidine
[no description available]		2.7230methylcytidine
n-methyladenosine
N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.		2.2110methyladenosine
2'-o-methyluridine
[no description available]		2.9340methyluridine
2'-o-methyladenosine
cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.		2.4420adenosines;
ether		fungal metabolite
n-acetylcytidine
N(4)-acetylcytidine : Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group.		2.2110acetamides;
cytidines;
secondary carboxamide		metabolite
5-formylcytidine
5-formylcytidine: found at the first position of the anticodon of methionine tRNA from bovine liver mitochondria; structure given in first source		2.2110
3'-deoxycytidine
[no description available]		3.5520
ribothymidine
ribothymidine : A methyluridine having a single methyl substituent at the 5-position on the uracil ring.		2.1710methyluridineantigen;
Escherichia coli metabolite;
human metabolite
4'-azidocytidine
4'-azidocytidine: antiviral; structure in first source		3.1710N-glycosyl compound
2'-c-methyladenosine
2'-C-methyladenosine: antiviral		3.1710
hcv 796
HCV 796: inhibits HCV RdRp; structure in first source		3.1710
oligonucleotides
[no description available]		2.110
anticodon
Anticodon: The sequential set of three nucleotides in TRANSFER RNA that interacts with its complement in MESSENGER RNA, the CODON, during translation in the ribosome.		210
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.04102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		2.7630guanosines;
purines D-ribonucleoside		fundamental metabolite
inosine
[no description available]		210inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ganciclovir
[no description available]		2.04102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
2'-o-methylguanosine
2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.		4.2550methylguanosinemetabolite
cyclopropavir
cyclopropavir: cyclopropavir is the (Z)-isomer; has antiviral activity; structure in first source		2.0410
3-deoxyguanosine
3'-deoxyguanosine : A 3'-deoxyribonucleoside having guanine as the nucleobase.		3.55203'-deoxyribonucleoside;
guanosines		EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
8-methylguanosine
8-methylguanosine: structure in first source		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Autosome
[description not available]		02.0210
ALS - Amyotrophic Lateral Sclerosis
[description not available]		02.2110
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)		02.2110
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.0110
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		02.0110